Oncotelic Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Oncotelic Therapeutics Inc in the second quarter 2026?
Oncotelic Therapeutics Inc achieved a return on average equity (ROE) of 124.17 % in its second quarter 2026, this is above OTLC's average return on equity of -160.09%.
Oncotelic Therapeutics Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $199 million

ROE fell compared to the first quarter 2026, despite the net income growth of % from the first quarter 2026.

Within the Major Pharmaceutical Preparations industry 7 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 47, from total ROE ranking in the first quarter 2026 at 51.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	3478.1 %	3550.22 %	3400.25 %	-0.68 %	-
Y / Y Net Income Change	62.04 %	-	-	-	-
Net Income (TTM) in Millions	247	247	249	-2	-4
Return On Equity (TTM)	124.17 %	183.27 %	350.26 %	-25.52 %	-55.39 %
OTLC's Total Ranking	# 47	# 51	# 16	# 2641	# 2597
Equity (TTM) in Millions	265	262	262	8	7
Seq. Equity Change	0.9 %	0.18 %	3140.66 %	9.23 %	2.93 %
Seq. Net Income Change	-	-	-	-	-

Back to OTLC Management Effectiveness >> OTLC's 5 Years Annual ROE >> Compare OTLC ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 8
Sector	# 14
Overall	# 47

Return On Equity Statistics
High	Average	Low
350.26 %	-160.09 %	-4239.83 %
(Dec 31 2025)		(Jun 30 2018)

OTLC Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	262	7	12	19	8
Y / Y Equity Change	3400.25 %	-35.6 %	-39.5 %	135.26 %	-34.63 %
Net Income in Millions	249	-5	-8	5	-11
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	95.15 %	-63.92 %	-70.67 %	24.37 %	-128.91 %

Back to OTLC Management Effectiveness >> OTLC's 5 Years Annual ROE >> Compare OTLC ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 95.15 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
OTLC's' Return on Equity at Yahoo Finance
OTLC's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for OTLC's Competitors
Subscribers only: Roe for Oncotelic Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for OTLC's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector	ROE
Meiragtx Holdings Plc	283.67 %
Silexion Therapeutics Corp	276.59 %
Actinium Pharmaceuticals Inc	213.46 %
Halozyme Therapeutics Inc	180.63 %
Capforce Inc	168.50 %
Aveanna Healthcare Holdings Inc	150.35 %
Liquidia Corporation	149.64 %
Interpace Biosciences Inc	142.98 %
Oncotelic Therapeutics Inc	124.17 %
Fortress Biotech Inc	118.22 %
Medpace Holdings Inc	110.15 %
Pulmatrix Inc	108.83 %
Arbutus Biopharma Corp	106.04 %
Rigel Pharmaceuticals Inc	96.49 %
Exelixis Inc	93.62 %
Alnylam Pharmaceuticals Inc	93.61 %
Eli Lilly And Company	92.54 %
Amgen Inc	89.32 %
Q32 Bio Inc	76.88 %
3m Company	76.55 %
Oramed Pharmaceuticals Inc	73.03 %
Tg Therapeutics Inc	72.30 %
Idexx Laboratories Inc	71.96 %
Elite Pharmaceuticals Inc	71.10 %
Zoetis Inc	68.87 %
Rallybio Corporation	68.56 %
Earth Science Tech Inc	66.17 %
Aurinia Pharmaceuticals Inc	59.00 %
Vaxart Inc	53.04 %
Qhslab Inc	51.21 %

Date modified: 2026-09-26T07:09:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.